Kiniksa Pharmaceuticals International, plc

Total Valuation

Kiniksa Pharmaceuticals International, plc carries a market capitalization of 5.94B, placing it among publicly traded companies globally. Its enterprise value stands at 4.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Kiniksa Pharmaceuticals International, plc currently has 77.98M shares outstanding.

Valuation Ratios

Kiniksa Pharmaceuticals International, plc trades at a trailing price-to-earnings ratio of 60.41. The price-to-sales ratio is 5.79, and the price-to-book ratio stands at 7.62.

Enterprise Valuation

On an enterprise value basis, Kiniksa Pharmaceuticals International, plc trades at an EV/EBITDA multiple of 43.80 and an EV/FCF ratio of 23.89. The EV/Sales ratio of 5.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 44.59 provides insight into valuation relative to core operating earnings.

Financial Position

Kiniksa Pharmaceuticals International, plc maintains a current ratio of 3.90, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Kiniksa Pharmaceuticals International, plc posts a return on equity of 14.04 and a return on invested capital of 12.12.

Taxes

Over the trailing twelve months, Kiniksa Pharmaceuticals International, plc has paid 33.59M in income taxes, reflecting an effective tax rate of 29.40.

Stock Price Statistics

Kiniksa Pharmaceuticals International, plc's stock has gained approximately 119.40299% over the past 52 weeks. The 50-day moving average sits at 71.45, while the 200-day moving average is 52.70.

Income Statement

Over the trailing twelve months, Kiniksa Pharmaceuticals International, plc generated 840.85M in revenue and converted that into 80.66M in net income, yielding earnings per share of 0.99. EBITDA reached 102.04M, while operating income came in at 100.25M.

Balance Sheet

Kiniksa Pharmaceuticals International, plc holds 525.93M in cash and equivalents against 8.90M in total debt, resulting in a net debt position of -175.68M. Total book value stands at 654.15M, with working capital of 497.39M providing operational flexibility.

Cash Flow

Kiniksa Pharmaceuticals International, plc produced 184.97M in operating cash flow over the past twelve months. After subtracting -2.13M in capital expenditures, free cash flow totaled 182.84M - equivalent to 2.40 per share.

Margins

Kiniksa Pharmaceuticals International, plc operates with a gross margin of 54.50, reflecting its pricing power and cost economics. The operating margin of 11.92 and net profit margin of 9.59 provide insight into operational efficiency.

Dividends & Yields

Scores

Kiniksa Pharmaceuticals International, plc posts an Altman Z-Score of 13.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.